Articles with public access mandates - Rachel GrishamLearn more
Not available anywhere: 4
Low-grade serous ovarian cancer: state of the science
B Slomovitz, C Gourley, MS Carey, A Malpica, IM Shih, D Huntsman, ...
Gynecologic oncology 156 (3), 715-725, 2020
Mandates: Cancer Research UK
Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome
DM Hyman, L Bakios, G Gualtiere, C Carr, RN Grisham, V Makker, ...
Gynecologic oncology 129 (1), 58-62, 2013
Mandates: US National Institutes of Health
Germline pathogenic variants and genetic counseling by ancestry in patients with epithelial ovarian cancer
TY Sia, A Maio, YM Kemel, KS Arora, SB Gordhandas, RM Kahn, ...
JCO Precision Oncology 7, e2300137, 2023
Mandates: US National Institutes of Health
Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets
RN Grisham, A Praiss, C Kyi, KJ Park
Advances in Oncology 3 (1), 47-53, 2023
Mandates: US National Institutes of Health
Available somewhere: 59
Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline
PA Konstantinopoulos, B Norquist, C Lacchetti, D Armstrong, RN Grisham, ...
Journal of Clinical Oncology 38 (11), 1222-1245, 2020
Mandates: US National Institutes of Health
BRAF mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer
RN Grisham, G Iyer, K Garg, D DeLair, DM Hyman, Q Zhou, A Iasonos, ...
Cancer 119 (3), 548-554, 2013
Mandates: US National Institutes of Health
Clinical utility of prospective molecular characterization in advanced endometrial cancer
TE Soumerai, MTA Donoghue, C Bandlamudi, P Srinivasan, MT Chang, ...
Clinical Cancer Research 24 (23), 5939-5947, 2018
Mandates: US National Institutes of Health
MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
BJ Monk, RN Grisham, S Banerjee, E Kalbacher, MR Mirza, I Romero, ...
Journal of clinical oncology 38 (32), 3753-3762, 2020
Mandates: US National Institutes of Health
Clinical and morphologic characteristics of MEK inhibitor–associated retinopathy: differences from central serous chorioretinopathy
JH Francis, LA Habib, DH Abramson, LA Yannuzzi, M Heinemann, ...
Ophthalmology 124 (12), 1788-1798, 2017
Mandates: US National Institutes of Health
Ovarian cancer mutational processes drive site-specific immune evasion
I Vázquez-García, F Uhlitz, N Ceglia, JLP Lim, M Wu, N Mohibullah, ...
Nature 612 (7941), 778-786, 2022
Mandates: US Department of Defense, US National Institutes of Health, Cancer Research …
Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer
DM Hyman, Q Zhou, A Iasonos, RN Grisham, AG Arnold, MF Phillips, ...
Cancer 118 (15), 3703-3709, 2012
Mandates: US National Institutes of Health
Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer
RN Grisham, BE Sylvester, H Won, G McDermott, D DeLair, R Ramirez, ...
Journal of Clinical Oncology 33 (34), 4099-4105, 2015
Mandates: US National Institutes of Health
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
RN Grisham, G Iyer, E Sala, Q Zhou, A Iasonos, D DeLair, DM Hyman, ...
International Journal of Gynecologic Cancer 24 (6), 2014
Mandates: US National Institutes of Health
Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study
O Zivanovic, DS Chi, Q Zhou, A Iasonos, JA Konner, V Makker, ...
Journal of Clinical Oncology 39 (23), 2594-2604, 2021
Mandates: US National Institutes of Health
Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management
R Grisham, B Ky, KS Tewari, DJ Chaplin, J Walker
Gynecologic oncology research and practice 5, 1-10, 2018
Mandates: US National Institutes of Health
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000–2013
A Oseledchyk, MM Leitao Jr, J Konner, RE O’Cearbhaill, D Zamarin, ...
Annals of Oncology 28 (12), 2985-2993, 2017
Mandates: US National Institutes of Health
Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes
YL Liu, K Breen, A Catchings, M Ranganathan, A Latham, DJ Goldfrank, ...
JCO oncology practice 18 (3), 201-209, 2022
Mandates: US National Institutes of Health
Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models
HC Wise, GV Iyer, K Moore, SM Temkin, S Gordon, C Aghajanian, ...
Scientific reports 9 (1), 18882, 2019
Mandates: US National Institutes of Health
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
MM Rubinstein, DM Hyman, I Caird, H Won, K Soldan, K Seier, A Iasonos, ...
Cancer 126 (6), 1274-1282, 2020
Mandates: US National Institutes of Health
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
D Zamarin, S Walderich, A Holland, Q Zhou, AE Iasonos, JM Torrisi, ...
Journal for Immunotherapy of Cancer 8 (1), 2020
Mandates: US Department of Defense, US National Institutes of Health
Publication and funding information is determined automatically by a computer program